331 related articles for article (PubMed ID: 22290600)
1. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.
De Angel RE; Conti CJ; Wheatley KE; Brenner AJ; Otto G; Degraffenried LA; Hursting SD
Mol Carcinog; 2013 Jun; 52(6):446-58. PubMed ID: 22290600
[TBL] [Abstract][Full Text] [Related]
2. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity.
Nogueira LM; Dunlap SM; Ford NA; Hursting SD
Endocr Relat Cancer; 2012 Feb; 19(1):57-68. PubMed ID: 22143497
[TBL] [Abstract][Full Text] [Related]
3. Effects of intermittent and chronic calorie restriction on mammalian target of rapamycin (mTOR) and IGF-I signaling pathways in mammary fat pad tissues and mammary tumors.
Dogan S; Johannsen AC; Grande JP; Cleary MP
Nutr Cancer; 2011; 63(3):389-401. PubMed ID: 21462085
[TBL] [Abstract][Full Text] [Related]
4. IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression.
Ford NA; Nunez NP; Holcomb VB; Hursting SD
Endocr Relat Cancer; 2013 Feb; 20(1):39-51. PubMed ID: 23152442
[TBL] [Abstract][Full Text] [Related]
5. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
6. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues.
Moore T; Beltran L; Carbajal S; Strom S; Traag J; Hursting SD; DiGiovanni J
Cancer Prev Res (Phila); 2008 Jun; 1(1):65-76. PubMed ID: 19138937
[TBL] [Abstract][Full Text] [Related]
7. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
8. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
Torres-Arzayus MI; Yuan J; DellaGatta JL; Lane H; Kung AL; Brown M
Cancer Res; 2006 Dec; 66(23):11381-8. PubMed ID: 17145884
[TBL] [Abstract][Full Text] [Related]
9. Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice.
Rossi EL; de Angel RE; Bowers LW; Khatib SA; Smith LA; Van Buren E; Bhardwaj P; Giri D; Estecio MR; Troester MA; Hair BY; Kirk EL; Gong T; Shen J; Dannenberg AJ; Hursting SD
Cancer Prev Res (Phila); 2016 May; 9(5):339-48. PubMed ID: 26869351
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
Riggio M; Polo ML; Blaustein M; Colman-Lerner A; Lüthy I; Lanari C; Novaro V
Carcinogenesis; 2012 Mar; 33(3):509-18. PubMed ID: 22180571
[TBL] [Abstract][Full Text] [Related]
11. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
12. Mammary cancer promotion by ovarian hormones involves IGFR/AKT/mTOR signaling.
Arumugam A; Parada J; Rajkumar L
Steroids; 2012 Jun; 77(7):791-7. PubMed ID: 22465879
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
14. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
15. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
17. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
18. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
19. Low-carbohydrate diet versus caloric restriction: effects on weight loss, hormones, and colon tumor growth in obese mice.
Wheatley KE; Williams EA; Smith NC; Dillard A; Park EY; Nunez NP; Hursting SD; Lane MA
Nutr Cancer; 2008; 60(1):61-8. PubMed ID: 18444137
[TBL] [Abstract][Full Text] [Related]
20. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
